课题基金 / 基金详情

Role of Endothelial Progenitor Cells in vascular Aging and Calcification

Role of Endothelial Progenitor Cells in vascular Aging and Calcification
内皮祖细胞在血管老化和钙化中的作用
批准号:
7780584
负责人:
Sundeep Khosla
金额:
$41.54万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-15 至 2015-03-31

项目摘要

项目成果

Sundeep Khosla的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 骨质疏松症和血管疾病影响着大量的老年人,越来越多的证据表明这两种疾病密切相关。动物和人类数据均表明,骨质疏松症与血管疾病和钙化有关。此外,血管钙化的过程似乎涉及与正常骨形成过程中使用的途径非常相似的途径。循环内皮祖细胞(EPCs)在内皮损伤后的血管修复中起着重要的作用。我们最近证实,血管疾病患者具有5- 8倍更高百分比的表达成骨表型的EPCs,如通过骨相关蛋白骨钙素(OCN)染色所评估的,这使我们提出了整体新颖的概念,即循环EPCs的成骨表型表达可以至少部分地解释,随着年龄的增长和动脉粥样硬化发生的血管钙化的增加。在目前,多学科的建议,利用多个PI机制(Lerman博士[血管疾病,心脏病学]和Khosla博士[骨代谢,内分泌学]),沿着血管生物学专家的帮助(Simari博士)作为共同研究者,我们将在我们的三个具体目标的背景下测试这一假设:目标1:使用来自接受心导管插入术的患者的纯化的EPCs,检验以下假设:与正常对照受试者相比,来自患有已确立的CAD的患者的循环EPCs表达成骨“转录体”(即,多个骨相关基因/途径),并具有增加的形成矿化结节和/或增强体外血管平滑肌细胞矿化的能力。目标二:在使用小鼠模型的体内研究中,检验了局部递送表达成骨表型的EPCs与AP染色阴性的EPC相比,Aim 2a(通过成骨细胞标记物AP染色定义)导致皮下骨形成(Aim 2a)和血管钙化(Aim 2b)增加。在接受冠状动脉心导管插入术的非梗阻性CAD患者的临床研究中,检验成骨/间充质标志物的表达(OCN,AP,Stro-1)与早期动脉粥样硬化相关(定义为内皮功能障碍)和血管钙化(通过血管内超声[IVUS]的敏感方法评估)(目的3a),这些成骨EPCs被冠状循环消耗(目的3b)。因此,拟议的研究使用多学科方法来测试新的假设。此外,这些研究的结果可能对我们理解血管钙化的启动机制以及血管系统和骨代谢之间日益增加的病理生理联系具有重要意义。 公共卫生相关性:衰老与骨质疏松症和血管疾病有关。此外,骨质疏松症患者(骨质减少)血管钙化的风险增加,这与血管中骨样结构的形成以及心脏病发作和中风有关。拟议的工作重点是循环细胞的作用,可能来自骨髓,在启动血管钙化,而不是正常的修复。这些研究应该帮助我们更好地了解血管钙化是如何发生的,也许还有将这一过程修改为更正常的修复过程的方法,这对预防和治疗衰老性心脏病具有重要意义。
英文摘要
DESCRIPTION (provided by applicant): Osteoporosis and vascular disease affect large numbers of aging individuals, and there is increasing evidence that the two disorders are closely related. Both animal and human data indicate that osteoporosis is associated with vascular disease and calcification. Moreover, the process of vascular calcification appears to involve pathways very similar to those utilized during normal bone formation. Circulating endothelial progenitor cells (EPCs) are now increasingly recognized as playing an important role in initiating vascular repair in response to endothelial injury. Our recent demonstration that patients with vascular disease have a 5- to 8-fold greater percentage of EPCs expressing an osteogenic phenotype, as assessed by staining for the bone- related protein, osteocalcin (OCN), has led us to propose the overall novel concept that expression of an osteogenic phenotype by circulating EPCs may explain, at least in part, the increase in vascular calcification that occurs with aging and in the setting of atherosclerosis. In the present, multi-disciplinary proposal utilizing the multiple PI mechanism (Dr. Lerman [Vascular Disease, Cardiology] and Dr. Khosla [Bone Metabolism, Endocrinology]), along with the help of an expert in Vascular Biology (Dr. Simari) as Co-Investigator, we will test this hypothesis within the context of our three Specific Aims: Aim 1: Using purified EPCs from patients undergoing cardiac catheterization, test the hypotheses that, as compared to normal control subjects, circulating EPCs from patients with established CAD express an osteogenic "transcriptosome" (i.e., multiple bone-related genes/pathways) and have an increased ability to form mineralized nodules and/or enhance mineralization of vascular smooth muscle cells in vitro. Aim 2: In in vivo studies using murine models, test the hypotheses that that local delivery of EPCs expressing an osteogenic phenotype (defined by staining for the osteoblastic marker, AP), as compared to EPCs negative for AP staining, leads to increases in both subcutaneous bone formation (Aim 2a) and vascular calcification (Aim 2b).and Aim 3:In clinical studies in patients with non-obstructive CAD undergoing coronary cardiac catheterization, test the hypotheses that the expression of osteogenic/mesenchymal markers (OCN, AP, Stro-1) by systemically circulating EPCs correlates with early atherosclerosis (as defined by endothelial dysfunction) and with vascular calcification (as assessed by the sensitive method of intravascular ultrasound [IVUS]) (Aim 3a), and that these osteogenic EPCs are being consumed by the coronary circulation (Aim 3b). The proposed studies thus test novel hypotheses using a multidisciplinary approach. Moreover, the results of these studies are likely to have significant implications for our understanding of the mechanisms initiating vascular calcification as well as the increasing pathophysiological link between the vasculature and bone metabolism. PUBLIC HEALTH RELEVANCE: Aging is associated with osteoporosis and with vascular (blood vessel) disease. In addition, patients with osteoporosis (who have reduced bone) have an increased risk of vascular calcification, which is associated with formation of bone-like structures in blood vessels and with heart attacks and strokes. The proposed work focuses on the role of circulating cells which likely arise from the bone marrow in initiating vascular calcification as opposed to normal repair. These studies should help us better understand how vascular calcification occurs, and perhaps ways of modifying the process into a more normal repair process, which would have important implications for the prevention and treatment of heart disease with aging.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the interactions of senescent immune cells and skeletal cells
  • 批准号:
    10629252
  • 项目类别:
  • 资助金额:
    $47.57万
  • 财政年份:
    2022
  • 负责人:
    Sundeep Khosla
  • 依托单位:
Defining the interactions of senescent immune cells and skeletal cells
  • 批准号:
    10424667
  • 项目类别:
  • 资助金额:
    $49.05万
  • 财政年份:
    2022
  • 负责人:
    Sundeep Khosla
  • 依托单位:
Skeletal Fragility
  • 批准号:
    10349486
  • 项目类别:
  • 资助金额:
    $51.41万
  • 财政年份:
    2019
  • 负责人:
    Sundeep Khosla
  • 依托单位:
Administrative and Biostatistics
  • 批准号:
    10561622
  • 项目类别:
  • 资助金额:
    $23.03万
  • 财政年份:
    2019
  • 负责人:
    Sundeep Khosla
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: